Publicacións en colaboración con investigadores/as de Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (19)

2023

  1. Clinical Characterisation and Comorbidities of Acquired Generalised Lipodystrophy: A 14-Year Follow-Up Study

    Journal of Clinical Medicine, Vol. 12, Núm. 23

  2. Clinical Spectrum of LMNA-Associated Type 2 Familial Partial Lipodystrophy: A Systematic Review

    Cells, Vol. 12, Núm. 5

  3. Hepatic levels of S-adenosylmethionine regulate the adaptive response to fasting

    Cell Metabolism, Vol. 35, Núm. 8, pp. 1373-1389.e8

  4. Increased musculature: A warning sign of familial partial lipodystrophy

    Endocrinologia, Diabetes y Nutricion, Vol. 70, Núm. 4, pp. 290-292

  5. Natural history and comorbidities of generalised and partial lipodystrophy syndromes in Spain

    Frontiers in Endocrinology, Vol. 14

  6. Should we suspect primary aldosteronism in patients with hypokalaemic rhabdomyolysis? A systematic review

    Frontiers in Endocrinology, Vol. 14

  7. The correlation of lipid profile and waist circumference with phenylalanine levels in adult patients with classical phenylketonuria

    Medicina Clinica, Vol. 160, Núm. 9, pp. 385-391

  8. The role of phenylalanine levels in the neuropsychological and neuroanatomical status of adult patients with phenylketonuria: The impact of fluctuations

    Journal of investigative medicine : the official publication of the American Federation for Clinical Research, Vol. 71, Núm. 2, pp. 149-158

  9. The value of waist circumference as a preditor of cardiovascular risk in adult patients with classic phenylketonuria

    Medicina Clinica, Vol. 161, Núm. 11, pp. 470-475

2022

  1. Lipodystrophy-associated progeroid syndromes

    Hormones, Vol. 21, Núm. 4, pp. 555-571

2021

  1. Lipid lowering treatment in patients with very high risk cardiovascular disease. Spanish Society of Cardiology Consensus Document for the use of PCSK9 inhibitors in clinical practice

    REC: CardioClinics, Vol. 56, Núm. 1, pp. 39-48

  2. Variable expressivity and allelic heterogeneity in type 2 familial partial lipodystrophy: The p.(thr528met) lmna variant

    Journal of Clinical Medicine, Vol. 10, Núm. 7

  3. Variable expressivity in type 2 familial partial lipodystrophy related to r482 and n466 variants in the lmna gene

    Journal of Clinical Medicine, Vol. 10, Núm. 6, pp. 1-9

2020

  1. Inflammatory and lipid regulation by cholinergic activity in epicardial stromal cells from patients who underwent open-heart surgery

    Journal of Cellular and Molecular Medicine, Vol. 24, Núm. 18, pp. 10958-10969

2018

  1. Bone mineral density in familial partial lipodystrophy

    Clinical Endocrinology, Vol. 88, Núm. 1, pp. 44-50

  2. Inflammatory myopathy in the context of an unusual overlapping laminopathy

    Archives of Endocrinology and Metabolism, Vol. 62, Núm. 3, pp. 376-382

  3. Lipopolysaccharide (LPS)-induced septic shock causes profound changes in myocardial energy metabolites in pigs

    Metabolomics, Vol. 14, Núm. 10

2017

  1. Evolution and bad prognostic value of advanced glycation end products after acute heart failure: Relation with body composition

    Cardiovascular Diabetology, Vol. 16, Núm. 1

2016

  1. Type 1 familial partial lipodystrophy: understanding the Köbberling syndrome

    Endocrine, Vol. 54, Núm. 2, pp. 411-421